Worldwide Use of RUCAM for Causality Assessment in 81,856 Idiosyncratic DILI and 14,029 HILI Cases Published 1993–Mid 2020: A Comprehensive Analysis
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Background: A large number of idiosyncratic drug induced liver injury (iDILI) and herb induced liver injury(HILI) cases of variable quality has been published but some are a matter of concern if the cases were not evaluated for causality using a robust causality assessment method (CAM) such as RUCAM (Roussel Uclaf Causality Assessment Method) as diagnostiinjuryc algorithm. The purpose of this analysis was to evaluate the worldwide use of RUCAM in iDILI and HILI cases. Methods: The PubMed database (1993–30 June 2020) was searched for articles by using the following key terms: Roussel Uclaf Causality Assessment Method; RUCAM; Idiosyncratic drug induced liver injury; iDILI; Herb induced liver injury; HILI. Results: Considering reports published worldwide since 1993, our analysis showed the use of RUCAM for causality assessment in 95,885 cases of liver injury including 81,856 cases of idiosyncratic DILI and 14,029 cases of HILI. Among the top countries providing RUCAM based DILI cases were, in decreasing order, China, the US, Germany, Korea, and Italy, with China, Korea, Germany, India, and the US as the top countries for HILI. Conclusions: Since 1993 RUCAM is certainly the most widely used method to assess causality in IDILI and HILI. This should encourage practitioner, experts, and regulatory agencies to use it in order to reinforce their diagnosis and to take sound decisions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“compositional complexity and lack of label trustworthiness of HDS confounds assessment.118,119”
From AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury (2023) · cites this paper as [118]
In the citing paper
“consideration of other causes of liver injury may have been overlooked or unappreciated when the tools were first developed.75,118”
From AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury (2023) · cites this paper as [118]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Danan, G., & Benichou, C. (1993) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(93)90101-6 · Cited by 1,481
Self-citationBjörnsson, E. S., Bergmann, O. M., Björnsson, H. K., Kvaran, R. B., & Olafsson, S. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.02.006 · Cited by 865
Incidence and Etiology of Drug-Induced Liver Injury in Mainland China
Shen, T., Liu, Y., Shang, J., Xie, Q., Li, J., Yan, M., Xu, J., Niu, J., Liu, J., Watkins, P. B., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.02.002 · Cited by 615 · cited 1×
“Shen, 2019 [48] 18,956 Various drugs Cohort comprized patients with DILI, but special DILI features related to individual drugs were not published.”
BackgroundAndrade, R. J., Lucena, I. M., Kaplowitz, N., García-Muņoz, B., Borraz, Y., Pachkoria, K., García-Cortés, M., Fernández, C. M., Pelaez, G., Rodrigo, L., et al. (2006) · Hepatology · doi:10.1002/hep.21424 · Cited by 309
Hepatotoxicity of green tea: an update
Mazzanti, G., Di Sotto, A., & Vitalone, A. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1521-x · Cited by 189
Herbal and Dietary Supplement-Induced Liver Injuries in the Spanish DILI Registry
Medina-Caliz, I., Garcia-Cortes, M., Gonzalez-Jimenez, A., Cabello, M. R., Robles-Diaz, M., Sanabria-Cabrera, J., Sanjuan-Jimenez, R., Ortega-Alonso, A., García-Muñoz, B., Moreno, I., et al. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.12.051 · Cited by 111
Systematic review of published data on herb induced liver injury
Byeon, J.-H., Kil, J.-H., Ahn, Y.-C., & Son, C.-G. (2019) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2019.01.006 · Cited by 105
Acute hepatitis associated with the use of green tea infusions
Jimenez-Saenz, M., & Martinez-Sanchez, M. D. C. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2005.11.041 · Cited by 95
Mazzanti, G., Moro, P. A., Raschi, E., Da Cas, R., & Menniti‐Ippolito, F. (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13171 · Cited by 81
Rathi, C., Pipaliya, N., Patel, R., Ingle, M., Phadke, A., & Sawant, P. (2017) · Annals of Hepatology · doi:10.5604/01.3001.0009.8600 · Cited by 61
Research works printed but not linked: 242
- Ke, L., Lu, C., Shen, R., Lu, T., Ma, B., and Hua, Y. (2020). Knowledge mapping of drug-induced liver injury: A scientometric investigation (2010–2019). Front. Pharmacol., in press. · DOI · Paper page
- Uetrecht, 2019, Mechanistic studies of idiosyncratic DILI: Clinical implications, Front. Pharmacol., 10, 837, 10.3389/fphar.2019.00837 · DOI
- Teschke, R., and Uetrecht, J. (2020). Mechanism of idiosyncratic drug induced liver injury (DILI): Unresolved basic issues. Ann. Transl. Med., In special issue: Unresolved basic issues in hepatology, guest editors Ralf Weiskirchen & Wolfgang Stremmel. · DOI · Paper page
- James, K., and David, C. (2018). Drug-Induced Liver Toxicity, Springer Protocols, Springer Nature.
- James, K., David, C.C., Minjun, C., and Yvonne, W. (2018). Causality assessment methods in drug-induced liver injury. Drug-Induced Liver Toxicity, Springer Nature. Chapter 27.
- Teschke, R., Danan, G., and Lewis, J.H. (2019). Special issue: Clinical drug induced liver injury: Current diagnostic and mechanistic challenges, guest editors: Rolf Teschke, Gaby Danan & James H. Lewis. Front. Pharmacol., Available online: https://www.frontiersin.org/research-topics/9104/clinical-drug-induced-liver-injury-current-diagnostic-and-mechanistic-challenges.
- Sarges, 2016, Drug-induced liver injury: Highlights from a review of the 2015 literature, Drug Saf., 39, 561, 10.1007/s40264-016-0427-8 · DOI · Paper page
- Shahbaz, 2017, Highlights of drug- and herb-induced liver injury in the literature from 2016, How best to translate new information into clinical practice?, Exp. Opin. Drug Metab. Toxicol., 13, 935, 10.1080/17425255.2017.1362391 · DOI · Paper page
- Real, 2019, Drug-induced liver injury: Highlights of the recent literature, Drug Saf., 42, 365, 10.1007/s40264-018-0743-2 · DOI · Paper page
- Rosenberg, 2020, Selected highlights from the recent literature of newly reported herbal and dietary supplement-induced liver injury, Adv. Res. Gastroenterol. Hepatol., 15, 555904, 10.19080/ARGH.2020.15.555904 · DOI
- Teschke, 2019, Idiosyncratic DILI: Analysis of 46, 266 cases assessed for causality by RUCAM and published from 2014 to early 2019, Front. Pharmacol., 10, 730, 10.3389/fphar.2019.00730 · DOI · Paper page
- Teschke, R., Eickhoff, A., Schulze, J., and Danan, G. (2020). Herb-induced liver injury (HILI) with 12,068 worldwide cases published with causality assessments by Roussel Uclaf Causality Assessment Method (RUCAM): An overview. Transl. Gastroenterol. Hepatol., in press. · DOI
- Danan, G., and Teschke, R. (2016). RUCAM in drug and herb induced liver injury: The update. Int. J. Mol. Sci., 17. · DOI · Paper page
- Danan, 2018, Drug-induced liver injury: Why is the Roussel Uclaf Causality Assessment Method (RUCAM) still used 25 years after its launch?, Drug Saf., 41, 735, 10.1007/s40264-018-0654-2 · DOI · Paper page
- Danan, 2019, Roussel Uclaf Causality Assessment Method for drug-induced liver injury: Present and Future, Front. Pharmacol., 10, 853, 10.3389/fphar.2019.00853 · DOI · Paper page
- Teschke, 2020, Editorial. DILI, HILI, RUCAM algorithm, and AI, the Artificial Intelligence: Provocative issues, progress, and proposals, Arch. Gastroenterol. Res., 1, 4
- Hayashi, P.H. (2016). Drug-Induced Liver Injury Network causality assessment: Criteria and experience in the United States. Int. J. Mol. Sci., 17. · DOI · Paper page
- Teschke, 2015, Drug-induced liver injury: Expanding our knowledge by enlarging population analysis with prospective and scoring causality assessment, Gastroenterology, 148, 1271, 10.1053/j.gastro.2015.04.027 · DOI
- Teschke, R., Eickhoff, A., Brown, A.C., Neuman, M.G., and Schulze, J. (2020). Diagnostic biomarkers in liver injury by drugs, herbs, and alcohol: Tricky dilemma after EMA correctly and officially retracted Letter of Support. Int. J. Mol. Sci., 21. · DOI · Paper page
- Nikolaos, T. (2020). Acetaminophen syn. paracetamol: Acute liver injury and acute on chronic liver failure with case analysis and causality assessment using RUCAM. Liver Failure: Acute and Acute on Chronic, Springer Nature.
- Bessone, F., Hermandez, N., Lucena, M.I., and Andrade, R.J. (2016). The Latin American DILI registry experience: A successful ongoing collaborative strategic initiative. Int. J. Mol. Sci., 17. · DOI · Paper page
- Bessone, 2019, When the creation of a consortium provides useful answers: Experience of The Latin American DILI Network (LATINDILIN), Clin. Liver Dis., 13, 51, 10.1002/cld.778 · DOI · Paper page
- Colaci, 2019, Idiosyncratic drug-induced acute liver failure: A challenging and distressing scenario, Curr. Drug Saf., 14, 94, 10.2174/1574886314666190215115434 · DOI
- Saturansky, 2019, Hepatic toxicity by methotrexate with weekly single doses associated with folic acid in rheumatoid and psoriatic arthritis. What is its real frequency?, Ann. Hepatol., 18, 765, 10.1016/j.aohep.2019.01.011 · DOI
- Lin, 2014, Drug-induced hepatotoxicity: Incidence of abnormal liver function tests consistent with volatile anaesthetic hepatitis in trauma patients, Liver Int., 34, 576, 10.1111/liv.12278 · DOI
- Ahmed, 2015, Resolution of ipilimumab induced severe hepatotoxicity with triple immunosuppressants therapy, BMJ Case Rep., 2015, bcr2014208102, 10.1136/bcr-2014-208102 · DOI · Paper page
- Laube, 2019, An unwanted complement: Rare case of potential liver injury induced by an interaction between ginseng and atorvastatin, Br. J. Clin. Pharm., 85, 1612, 10.1111/bcp.13927 · doi:10.1111/bcp.13927
- Worland, 2020, Retrospective study of idiosyncratic drug-induced liver injury from infliximab in an inflammatory bowel disease cohort: The IDLE study, Ann. Gastroenterol., 33, 162
- Sridharan, K., Al Daylami, A., Ajjawi, R., and Al Ajooz, H.A.M. (2020). Drug-induced liver injury in critically ill children taking antiepileptic drugs: A retrospective study. Curr. Ther. Res., in press. · DOI
- Becker, 2019, Drug and herb-induced liver injury: A critical review of Brazilian cases with proposals for the improvement of causality assessment using RUCAM, Ann. Hepatol., 18, 742, 10.1016/j.aohep.2019.03.010 · DOI
- Yan, 2006, Rofecoxib-induced hepatotoxicity: A forgotten complication of the coxibs, Can. J. Gastroenterol., 20, 351, 10.1155/2006/356434 · DOI
- Nhean, 2019, Probable hepatotoxicity with dolutegravir: Report of two cases and review of the literature, Aids, 33, 1261, 10.1097/QAD.0000000000002191 · doi:10.1097/qad.0000000000002191
- Hou, 2012, Hospital admissions for drug-induced liver injury: Clinical features, therapy, and outcomes, Cell Biochem. Biophys., 64, 77, 10.1007/s12013-012-9373-y · DOI
- Lv, 2012, NAT2 genetic polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in Chinese community population, Ann. Hepatol., 11, 700, 10.1016/S1665-2681(19)31446-2 · DOI
- Hao, 2014, RUCAM scale-based diagnosis, clinical features and prognosis of 140 cases of drug-induced liver injury, Chin. J. Hepatol., 22, 938
- Ou, 2015, Causes, clinical features and outcomes of drug-induced liver injury in hospitalized patients in a Chinese tertiary care hospital, SpringerPlus, 4, 802, 10.1186/s40064-015-1600-8 · DOI · Paper page
- Zhu, 2015, Causes, features, and outcomes of drug-induced liver injury in 69 children from China, Gut Liver, 9, 525, 10.5009/gnl14184 · DOI
- Lu, 2016, Clinical characteristics of drug-induced liver injury and related risk factors, Exp. Med., 12, 2606, 10.3892/etm.2016.3627 · DOI
- Yang, 2016, Clinical characteristics of drug-induced liver injury and primary biliary cirrhosis, World J. Gastroenterol., 22, 7579, 10.3748/wjg.v22.i33.7579 · DOI
- Zhu, 2016, Comparison between Chinese herbal medicine and Western medicine-induced liver injury of 1985 patients, J. Gastroenterol. Hepatol., 31, 1476, 10.1111/jgh.13323 · DOI · Paper page
- Naiqiong, 2017, A multicenter and randomized controlled trial of Bicyclol in the treatment of statin-induced liver injury, Med. Sci. Monit., 23, 5760, 10.12659/MSM.904090 · DOI
- Li, X.L., Liu, X., Song, Y., Hong, R.T., and Shi, H. (2018). Suspected drug-induced liver injury associated with iguratimod: A case report and review of the literature. BMC Gastroenterol., 18. · DOI
- Song, 2018, Posaconazole-associated severe hyperbilirubinemia in acute myeloid leukemia following chemotherapy: A case report, World J. Clin. Cases, 6, 1206, 10.12998/wjcc.v6.i16.1206 · DOI
- Tao, 2018, Genetic polymorphisms of UGT 1A1 and susceptibility to anti-tuberculosis drug-induced liver injury: A RUCAM-based case-control study, Int. J. Immunopathol. Pharm., 32, 1, 10.1177/2058738418816288 · DOI
- Liao, 2019, A rare case of cefapime-induced cholestatic liver injury, Tzu Chi Med. J., 31, 124, 10.4103/tcmj.tcmj_151_18 · DOI
- Xing, 2019, Assessment of cholestasis in drug-induced liver injury by different methods, Medicine, 98, e14399, 10.1097/MD.0000000000014399 · DOI
- Ma, 2020, Fenofibrate-induced hepatotoxicity: A case with a special feature that is different from those in the LiverTox database, J. Clin. Pharm., 45, 204
- Tao, B., Yang, M., Chen, H., Pan, H., Liu, W., Yi, H., and Tang, S. (2020). Association of ABO blood group and antituberculosis drug-induced liver injury: A case-control study from a Chinese Han population. J. Clin. Pharm. · DOI
- Wang, S., Shangguan, Y., Ding, C., Li, P., Ji, Z., Shao, J., Fang, H., Yang, M., Shi, P., and Wu, J. (2020). Risk factors for acute liver failure among inpatients with anti-tuberculosis drug-induced liver injury. J. Int. Med. Res., 48. · DOI
- Yang, 2019, Comparison of different liver test thresholds for drug-induced liver injury: Updated RUCAM versus other methods, Front. Pharmacol., 10, 816, 10.3389/fphar.2019.00816 · DOI · Paper page
- Restrepo, 2013, Abendazole-induced liver injury: A case report, Colomb. Med., 44, 118, 10.25100/cm.v44i2.1021 · DOI
- Amariles, 2019, Epidemiology of drug-induced liver injury in a university hospital from Colombia: Updated RUCAM being used for prospective causality assessment, Ann. Hepatol., 18, 501, 10.1016/j.aohep.2018.11.008 · DOI
- Alhaddad, 2020, Presentations, causes and outcomes of drug-induced liver injury in Egypt, Sci. Rep., 10, 5124, 10.1038/s41598-020-61872-9 · DOI · Paper page
- Danan, 1993, Causality assessment of adverse reactions to drugs—II. An original model for validation of drug causality assessment methods: Case reports with positive rechallenge, J. Clin. Epidemiol., 46, 1331, 10.1016/0895-4356(93)90102-7 · DOI · Paper page
- Arotcarena, 2004, Pioglitazone-induced acute severe hepatitis, Gastroenterol. Clin. Biol., 28, 609
- Moch, 2012, Etifoxine-induced acute hepatitis: A case series, Clin. Res. Hepatol. Gastroenterol., 36, e85, 10.1016/j.clinre.2012.04.002 · DOI
- Carrier, 2013, Acute liver toxicity due to methylprednisolone: Consider this diagnosis in the context of autoimmunity, Clin. Res. Hepatol. Gastroenterol., 37, 100, 10.1016/j.clinre.2012.10.015 · DOI
- Ripault, 2013, Crizotinib-induced acute hepatitis: First case with relaps after reintroduction with reduced dose, Clin. Res. Hepatol. Gastroenterol., 37, e21, 10.1016/j.clinre.2012.10.003 · DOI
- Dumortier, 2017, Methylprednisolone liver toxicity: A new case and a French regional pharmacovigilance survey, Clin. Res. Hepatol. Gastroenterol., 41, 497, 10.1016/j.clinre.2017.03.008 · DOI
- Meunier, 2018, Recent advances in hepatotoxicity of non steroidal anti-inflammatory drugs, Ann. Hepatol., 17, 187, 10.5604/01.3001.0010.8633 · DOI
- Douros, 2014, Flupirtine-induced liver injury-Seven cases from the Berlin Case-control Surveillance Study and review of the German spontaneous adverse drug reaction reporting database, Eur. J. Clin. Pharm., 70, 453, 10.1007/s00228-013-1631-4 · DOI
- Douros, 2014, Drug-induced liver injury: Results from the hospital-based Berlin Case-Control Surveillance Study, Br. J. Clin. Pharm., 79, 988, 10.1111/bcp.12565 · DOI · Paper page
- Buechter, 2018, Potential triggering factors of acute liver failure as a first manifestation of autoimmune hepatitis-a single center experience of 52 adult patients, World J. Gastroenterol., 24, 1410, 10.3748/wjg.v24.i13.1410 · DOI
- Dragoi, 2018, Proteomics analysis of monocyte-derived hepatocyte-like cells identifies integrin beta 3 as a specific biomarker for drug-induced liver injury by diclofenac, Front. Pharmacol., 9, 699, 10.3389/fphar.2018.00699 · DOI · Paper page
- Teschke, 2018, Review: Drug induced liver injury with analysis of alternative causes as confounding variables, Br. J. Clin. Pharm., 84, 1467, 10.1111/bcp.13593 · DOI
- Teschke, 2018, Review. Top-ranking drugs out of 3312 drug-induced liver injury cases evaluated by the Roussel Uclaf Causality Assessment Method, Expert Opin. Drug Metab. Toxicol., 14, 1169
- Weber, 2019, Early ALT response to corticosteroid treatment distinguishes idiosyncratic drug-induced liver injury from autoimmune hepatitis, Liver Int., 39, 1906, 10.1111/liv.14195 · DOI · Paper page
- Jacobsen, 2012, Hepatotoxicity associated with statins: Reports of idiosyncratic liver injury post-marketing, J. Hepatol., 56, 374, 10.1016/j.jhep.2011.07.023 · DOI · Paper page
- Hoofnagle, 2016, Categorization of drugs implicated in causing liver injury: Critical assessment based on published case reports, Hepatology, 63, 590, 10.1002/hep.28323 · DOI · Paper page
- Harugeri, 2009, Montelukast induced acute hepatocellular injury, J. Postgrad. Med., 55, 141, 10.4103/0022-3859.52850 · DOI
- Devarbhavi, 2010, Single center experience with drug-induced liver injury from India: Causes, outcome, prognosis, and predictors of mortality, Am. J. Gastroenterol., 105, 2396, 10.1038/ajg.2010.287 · DOI · Paper page
- Taneja, 2017, Acute liver failure due to Etodolac, a selective cycloxygenase- 2 (COX-2) inhibitor non-steroidal anti-inflammatory drug established by RUCAM-based causality assessment, Ann. Hepatol., 16, 818, 10.5604/01.3001.0010.2829 · DOI
- Dutta, 2020, Haloperidol induced hepatotoxicity: A case report, Ann. Clin. Case Rep., 5, 1827
- Kulkarni, 2020, Steroids as rescue therapy for vitamin A-induced acute liver failure, BMJ Case Rep. CP, 13, e233902, 10.1136/bcr-2019-233902 · DOI
- Gluck, 2011, Acute amiodarone liver toxicity likely due to ischemic hepatitis, Isr. Med. Assoc. J., 13, 748
- Rigato, 2007, Drug-induced acute cholestatic liver damage in a patient with mutation of UGT1A1, Nat. Clin. Pr. Gastroenterol. Hepatol., 4, 43
- Licata, 2010, Clinical course and outcomes of drug-induced liver injury: Nimesulide as the first implicated medication, Dig. Liver Dis., 42, 143, 10.1016/j.dld.2009.06.009 · DOI
- Abenavoli, 2013, Severe hepatitis by cyproterone acetate: Role of corticosteroids. A case report, Ann. Hepatol., 1, 152, 10.1016/S1665-2681(19)31399-7 · DOI
- Ferrajolo, 2017, Antibiotic-induced liver injury in paediatric outpatients: A case-control study in primary care databases, Drug Saf., 40, 305, 10.1007/s40264-016-0493-y · DOI
- Licata, 2017, A focus on epidemiology of drug-induced liver injury; analysis of a prospective cohort, Eur. Rev. Pharm. Sci., 21, 112
- Giacomelli, A., Rusconi, S., Falvella, F.S., Oreni, M.L., Cattaneo, D., Cozzi, V., Renisi, G., Monge, E., Cheli, S., and Clementi, E. (2018). Clinical and genetic determinants of nevirapine plasma through concentration. SAGE Open Med., 6. · DOI
- Licata, 2018, Rivaroxaban-induced hepatotoxicity: Review of the literature and report of new cases, Eur. J. Gastroenterol. Hepatol., 30, 226, 10.1097/MEG.0000000000001030 · DOI
- Lovero, 2018, A case of severe transaminase elevation following a single Ustekinumab dose with remission after drug withdrawal, Curr. Drug Saf., 13, 221, 10.2174/1574886313666180719165212 · doi:10.2174/1574886313666180719165212
- Masumoto, 2003, Diagnosis of drug-induced liver injury in Japanese patients by criteria of the Consensus Meetings in Europe, Hepatol. Res., 25, 1, 10.1016/S1386-6346(02)00148-1 · DOI
- Hanatani, 2014, A detection algorithm for drug-induced liver injury in medical information databases using the Japanese diagnostic scale and its comparison with the Council for International Organizations of Medical Sciences/the Roussel Uclaf Causality Assessment Method scale, Pharm. Drug Saf., 23, 984
- Niijima, 2017, Drug-induced liver injury caused by Ipragliflozin administration with causality established by a positive lymphocyte transformation test (LTT) and the Roussel Uclaf Causality Assessment Method (RUCAM): A case report, Ann. Hepatol., 16, 308, 10.5604/16652681.1231594 · DOI
- Ji, 2017, A rare case of methimazole-induced cholestatic jaundice in an elderly man of Asian ethnicity with hyperthyroidism: A case report, Medicine, 96, e9093, 10.1097/MD.0000000000009093 · DOI
- Aiso, 2019, Analysis of 307 cases with drug-induced liver injury between 2010 and 2018 in Japan, Hepatol. Res., 49, 105, 10.1111/hepr.13288 · DOI · Paper page
- Kishimoto, 2019, Clonazepam-induced liver dysfunction, severe hyperlipidaemia, and hyperglycaemic crisis: A case report, SAGE Open Med. Cases Rep., 7, 1
- Hiraki, 2020, An unusual case of acute liver failure caused by adjuvant oral Tegafur-Uracil with folinate therapy for colon cancer patient: A case report, J. Gastrointest. Cancer, 51, 296, 10.1007/s12029-019-00228-7 · DOI
- Kakisaka, 2019, Unfavorable prognosis of patients with acute liver injury due to drug-induced liver injury and acute exacerbation of hepatitis B virus infection, Hepatol. Res., 49, 1286, 10.1111/hepr.13397 · DOI
- Choi, 2008, Acute drug-induced hepatitis caused by albendazole, J. Korean Med. Sci., 23, 903, 10.3346/jkms.2008.23.5.903 · DOI · Paper page
- Suk, 2012, A prospective nationwide study of drug-induced liver injury in Korea, Am. J. Gastroenterol., 107, 1380, 10.1038/ajg.2012.138 · DOI · Paper page
- Son, 2015, Drug-induced liver injury by Western medication, J. Int. Korean Med., 36, 69
- Woo, 2015, Drug-induced liver injury: A 2-year retrospective study of 1169 hospitalized patients in a single medical center, Phytomedicine, 22, 1201, 10.1016/j.phymed.2015.10.002 · DOI · Paper page
- Kwon, 2019, Nimesulide-induced hepatotoxicity: A systemic review and meta-analysis, PLoS ONE, 14, e0209264, 10.1371/journal.pone.0209264 · DOI
- Thalha, 2018, Kombiglyze (metformin and saxagliptin)-induced hepatotoxicity in a patient with non-alcoholic fatty liver disease, JGH Open, 2, 242, 10.1002/jgh3.12083 · DOI
- 2018, Non-cholestatic acute hepatitis following Candesartan administration, Br. J. Clin. Pharm., 84, 204, 10.1111/bcp.13406 · DOI
- Essaid, 2010, Cholestatic acute hepatitis induced by tadalafil (Cialis®), Gastroenterol. Clin. Biol., 34, e1, 10.1016/j.gcb.2010.01.001 · DOI
- Costa-Moreira, P., Gaspar, R., Pereira, P., Lopes, S., Canao, P., Lopes, J., Carneiro, F., and Macedo, G. (2020). Role of liver biopsy in the era of clinical prediction scores for “drug-induced liver injury” (DILI): Experience of a tertiary referral hospital. Virchows Arch. · DOI
- Alqrinawi, S.H., Akbar, N., AlFaddag, H., Akbar, S., Akbar, L., Butt, S.A., and Aljawad, M. (2019). Menotrophin induced autoimmune hepatitis. Case Rep. Gastrointest. Med. · DOI
- Miljkovic, 2011, Consistency between causality assessments obtained with two scales and their agreement with clinical judgments in hepatotoxicity, Pharm. Drug Saf., 20, 272
- Miljkovic, 2012, Accuracy and reproducibility of two scales in causality assessment of unexpected hepatotoxicity, J. Clin. Pharm., 37, 196
- Wai, 2006, Presentation of drug-induced liver injury in Singapore, Singap. Med. J., 47, 116
- Stricker, 1996, Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid, Arch. Int. Med., 156, 1327, 10.1001/archinte.1996.00440110099013 · DOI · Paper page
- Andrade, 2005, Spanish Group for the Study of Drug-induced Liver Disease. Drug-induced liver injury: An analysis of 461 incidences submitted to the Spanish registry over a 10-year period, Gastroenterology, 129, 512, 10.1016/j.gastro.2005.05.006 · DOI · Paper page
- Lucena, 2008, Evaluation of Naranjo Adverse Drug Reactions Probability Scale in causality assessment of drug-induced liver injury, Aliment. Pharm., 27, 780, 10.1111/j.1365-2036.2008.03655.x · DOI · Paper page
- Lucena, 2011, Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles, Gastroenterology, 141, 338, 10.1053/j.gastro.2011.04.001 · DOI · Paper page
- Lucena, 2011, Recurrent drug-induced liver injury (DILI) with different drugs in the Spanish Registry: The dilemma of the relationship to autoimmune hepatitis, J. Hepatol., 55, 820, 10.1016/j.jhep.2010.12.041 · DOI · Paper page
- Stephens, 2015, on behalf of the Spanish DILI Registry and the SLatinDILI Network. Distinct phenotype of hepatotoxicity associated with illicit use of anabolic androgenic steroids, Aliment. Pharm., 41, 116, 10.1111/apt.13023 · DOI · Paper page
- Tong, 2015, Liver transplant in a patient under methylphenidate therapy: A case report and review of the literature, Case Rep. Pediatr., 2015, 437298
- Stephens, 2016, Spanish DILI registry. Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury, J. Hepatol., 65, 532, 10.1016/j.jhep.2016.05.003 · DOI · Paper page
- Conde, 2018, Non-invasive prediction of NAFLD severity: A comprehensive, independent validation of previously postulated serum microRNA biomarkers, Sci. Rep., 8, 10606, 10.1038/s41598-018-28854-4 · DOI
- Machlab, 2019, Apixaban-induced liver injury, Rev. Esp. Enferm. Dig., 111, 161
- Zoubek, 2019, Liver injury after methylprednisolone pulses: A disputable cause of hepatotoxicity. A case series and literature review, United Eur. Gastroenterol. J., 7, 825, 10.1177/2050640619840147 · DOI
- Olsson, 2005, Outcome and prognostic markers in severe drug-induced liver disease, Hepatology, 42, 481, 10.1002/hep.20800 · DOI · Paper page
- Klinteberg, 2006, Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic, Aliment. Pharm., 24, 1187, 10.1111/j.1365-2036.2006.03117.x · DOI · Paper page
- Kalaitzakis, 2007, Long-term follow-up of patients with mild to moderate drug-induced liver injury, Aliment. Pharm., 26, 79, 10.1111/j.1365-2036.2007.03355.x · DOI
- 2014, Epidemiology and risk factors for idiosyncratic drug-induced liver injury, Semin Liver Dis., 34, 115, 10.1055/s-0034-1375953 · DOI
- Goossens, 2013, Severe immune-mediated drug-induced liver injury linked to ibandronate: A case report, J. Hepatol., 59, 1139, 10.1016/j.jhep.2013.06.003 · DOI
- Russmann, 2014, Rivaroxaban postmarketing risk of liver injury, J. Hepatol., 61, 293, 10.1016/j.jhep.2014.03.026 · DOI
- Scalfaro, 2017, Preliminary results of a novel algorithmic method aiming to support initial causality assessment of routine pharmacovigilance case reports for medication-induced liver injury: The PV-RUCAM, Drug Saf., 40, 715, 10.1007/s40264-017-0541-2 · DOI · Paper page
- Schneider, 2017, Drug-induced autoimmune hepatitis following treatment with Zoledronic acid, Case Rep. Gastroenterol., 11, 440, 10.1159/000479314 · DOI
- Bertoli, 2017, Atovaquone/proguanil-induced autoimmune-like hepatitis, Hepatol. Commun., 1, 293, 10.1002/hep4.1039 · DOI
- Visentin, 2018, Drug-induced bile duct injury, BBA Mol. Basis Dis., 1864, 1498, 10.1016/j.bbadis.2017.08.033 · DOI
- Treeprasertsuk, 2010, The predictors of complications in patients with drug-induced liver injury caused by antimicrobial agents, Aliment. Pharm., 11, 1200, 10.1111/j.1365-2036.2010.04292.x · DOI
- Sobhonslidsuk, A., Poovorawan, K., Soonthornworasiri, N., Pangnum, W., and Phaosawasdi, K. (2016). The incidence, presentation, outcomes, risk of mortality and economic data of drug-induced liver injury from a national database in Thailand: A population-base study. BMC Gastroenterol., 16. · DOI
- Chayanupatkul, 2020, Acute liver failure secondary to drug-induced liver injury, Clin. Liver Dis., 24, 75, 10.1016/j.cld.2019.09.005 · DOI
- Duzenli, 2019, Drug-induced liver injury caused by Phenprobamate: Strong probability due to repeated toxicity, Eur. J. HepatoGastroenterol., 9, 49
- Hussaini, 2007, Antibiotic therapy: A major cause of drug-induced jaundice in southwest England, Eur. J. Gastroenterol. Hepatol., 19, 15, 10.1097/01.meg.0000250581.77865.68 · DOI
- Daly, 2009, HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin, Nat. Genet., 41, 816, 10.1038/ng.379 · DOI · Paper page
- Spraggs, 2011, HLA-DQA1*02, 01 is a major risk factor for Lapatinib-induced hepatotoxicity in women with advanced breast cancer, J. Clin. Oncol., 29, 667, 10.1200/JCO.2010.31.3197 · DOI · Paper page
- Islam, 2014, A case of anastrazole-related drug-induced autoimmune hepatitis, Clin. J. Gastroenterol., 7, 414, 10.1007/s12328-014-0512-4 · DOI
- Dyson, 2016, Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use, J. Hepatol., 64, 234, 10.1016/j.jhep.2015.07.041 · DOI
- Abbara, A., Chitty, S., Roe, J.K., Ghani, R., Collin, S.M., Ritchie, A., Kon, O.M., Dzvova, J., Davidson, H., and Edwards, T.E. (2017). Drug-induced liver injury from antituberculous treatment: A retrospective study from a large TB centre in the UK. BMC Infect. Dis., 17. · DOI · Paper page
- Vliegenthart, 2017, MicroRNA-122 can be measured in capillary blood which facilitates point-of-care testing for drug-induced liver injury, Br. J. Clin. Pharm., 83, 2027, 10.1111/bcp.13282 · DOI
- Fontana, 2005, Acute liver failure due to amoxicillin and amoxicillin/clavulanate, Dig. Dis. Sci., 10, 1785, 10.1007/s10620-005-2938-5 · DOI
- Lee, 2005, Hepatic findings in long-term clinical trials of ximelagatran, Drug Saf., 28, 351, 10.2165/00002018-200528040-00006 · DOI · Paper page
- Stojanovski, 2007, Atomoxetine-induced hepatitis in a child, Clin. Toxicol., 45, 51, 10.1080/15563650600795644 · DOI · Paper page
- Lammert, 2008, Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: Search for signals, J. Hepatol., 47, 2003, 10.1002/hep.22272 · DOI · Paper page
- Singla, 2010, Uncommon cause of acute drug-induced liver injury following mammoplasty, Gastroenterol. Res., 3, 171
- Nabha, 2012, Etravirine induced severe hpersensitivity reaction and fulminant hepatitis: A case report and review of the literature, J. Aids Clin. Res., 3, 005
- Sprague, D., and Bamha, K. (2012). Drug-induced liver injury due to varenicline. BMC Gastroenterol., 12. · DOI
- Markova, 2013, Association of CYP2C9*2 with bosentan-induced liver injury, Clin. Pharm., 94, 678
- Marumoto, 2013, Trial and error: Investigational drug induced liver injury, a case series report, Hawaii J. Med. Public Health, 72, 30
- Bohm, 2014, Case report and cohort analysis of drug-induced liver injury associated with daptomycin, Antimicrob. Agents Chemother., 58, 4902, 10.1128/AAC.03157-14 · DOI
- Cheetham, 2014, An automated causality assessment algorithm to detect drug-induced liver injury in electronic medical record data, Pharm. Drug Saf., 23, 601
- Lim, 2014, A challenge for diagnosing acute liver injury with concomitant/sequential exposure to multiple drugs: Can causality assessment scales be utilized to identify the offending drug?, Case Rep. Pediatr., 2014, 156389
- Russo, 2014, Spectrum of statin hepatotoxicity: Experience of the drug-induced liver injury network, Hepatology, 60, 679, 10.1002/hep.27157 · DOI · Paper page
- Veluswamy, 2014, Adverse drug reaction: Pomalidomide-induced liver injury, Lancet, 383, 2125, 10.1016/S0140-6736(14)61030-8 · DOI
- Baig, 2015, Acute liver failure after initiation of rivaroxaban: A case report and review of the literature, N. Am. J. Med. Sci., 7, 407, 10.4103/1947-2714.166221 · DOI
- Hammerstrom, 2015, Possible Amlodipine-induced hepatotoxicity after stem cell transplant, Ann. Pharm., 49, 135
- Stine, 2015, Hepatic decompensation likely attributable to Simeprevir in patients with advanced cirrhosis, Dig. Dis. Sci., 60, 1031, 10.1007/s10620-014-3422-x · DOI
- Tang, 2015, Acute hepatocellular drug-induced liver injury from bupropion and doxycycline, ACG Case Rep. J., 3, 66, 10.14309/crj.2015.103 · DOI
- Unger, 2016, Ciprofloxacin exposure leading to fatal hepatotoxicity: An unusual correlation, Am. J. Case Rep., 17, 676, 10.12659/AJCR.899080 · doi:10.12659/ajcr.899080
- Gharia, 2017, Letrozole-induced hepatitis with autoimmune features: A rare adverse drug reaction with review of the relevant literature, Oxf. Med. Case Rep., 2017, omx074, 10.1093/omcr/omx074 · doi:10.1093/omcr/omx074
- Nicoletti, 2017, International Drug-Induced Liver Injury Consortium, Drug-Induced Liver Injury Network Investigators, and International Serious Adverse Events Consortium. Association of liver injury from specific drugs or group of drugs with polymorphisms in HLA and other genes in a Genome-wide Association Study, Gastroenterology, 152, 1078, 10.1053/j.gastro.2016.12.016 · DOI · Paper page
- Gayam, 2018, Drug-Induced Liver Injury: An institutional case series and review of literature, J. Investig. Med. High Impact Case Rep., 6, 1
- Hayashi, 2018, Long-term outcomes after drug-induced liver injury, Curr. Hepatol. Rep., 17, 292, 10.1007/s11901-018-0411-0 · DOI · Paper page
- Patel, S., Mendler, M.H., Valasek, M.A., and Tsunoda, S.M. (2018). Drug-induced liver injury associated with the use of Everolimus in a liver transplantant patient. Case Rep. Transpl. · DOI · Paper page
- Shamberg, 2018, Hepatotoxicity of inflammatory bowel disease medications, J. Clin. Gastroenterol., 52, 674, 10.1097/MCG.0000000000001084 · doi:10.1097/mcg.0000000000001084
- Cirulli, 2019, Drug-Induced Liver Injury Network (DILIN) investigators; International DILI consortium (iDILIC). A missense variant in PTPN22 is a risk factor for drug-induced liver injury, Gastroenterology, 56, 1707, 10.1053/j.gastro.2019.01.034 · DOI · Paper page
- Nicoletti, 2019, International Drug-Induced Liver Injury Consortium (iDILIC). Drug-induced liver injury due to Flucloxacillin: Relevance of multiple human leukocyte antigen alleles, Clin. Pharm., 106, 245
- Sandritter, 2019, An electronic medical records-based approach to identify idiosyncratic drug-induced liver injury in children, Sci. Rep., 9, 18090, 10.1038/s41598-019-54075-4 · DOI · Paper page
- Shumar, 2019, Memantine-induced liver injury with probable causality as assessed using the Roussel Uclaf Causality Assessment Method (RUCAM), ACG Case Rep. J., 6, e00184, 10.14309/crj.0000000000000184 · DOI
- Tsung, 2019, Liver injury is most commonly due to hepatic metastases rather than drug hepatotoxicity during pembrolizumab immunotherapy, Aliment. Pharm., 50, 800, 10.1111/apt.15413 · DOI · Paper page
- Xie, 2019, Anastrozole-induced liver injury after a prolonged latency: A very rare complication of a commonly prescribed medication, BMJ Case Rep., 12, e231741, 10.1136/bcr-2019-231741 · doi:10.1136/bcr-2019-231741
- Ghabril, 2020, Significant medical comorbidities are associated with lower causality scores in patients presenting with suspected drug-induced liver injury, Clin. Transl. Gastroenterol., 11, e00141, 10.14309/ctg.0000000000000141 · DOI
- Mehershahi, 2020, Enoxaparin-induced liver injury, Case Rep. Gastroenterol., 14, 315, 10.1159/000508471 · doi:10.1159/000508471
- Mullins, 2020, Drug-induced liver injury (DILI) with Micafungin: The importance of causality assessment, Ann. Pharm., 54, 526
- Smith, 2016, Fulminant liver failure and transplantation after use of dietary supplements, Med. J. Aust., 204, 30, 10.5694/mja15.00816 · DOI
- Stadlbauer, 2005, Hepatotoxicity of NONI juice: Report of two cases, World J. Gastroenterol., 11, 4758, 10.3748/wjg.v11.i30.4758 · DOI · Paper page
- Barcelos, S.T.A., Dall’Oglio, V.M., de Araújo, A., and Schmidt Cerski, C.T. (2019). Sinusoidal obstruction syndrome secondary the intake of Senecio brasiliensis: A case report. Ann. Hepatol., in press.
- Yuen, 2006, Traditional Chinese Medicine causing hepatotoxicity in patients with chronic hepatitis B infection: A 1-year prospective study, Aliment. Pharm., 24, 1179, 10.1111/j.1365-2036.2006.03111.x · DOI · Paper page
- Cheung, 2009, Liver injury associated with the use of Fructus Psoraleae (Bol-gol-zhee or Bu-gu-zhi) and its related proprietary medicine, Clin. Toxicol., 47, 683, 10.1080/15563650903059136 · DOI · Paper page
- Chau, 2011, Causality assessment of herb-induced liver injury using multidisciplinary approach and the Roussel Uclaf Causality Assessment Method (RUCAM), Clin. Toxicol., 49, 34, 10.3109/15563650.2010.537662 · DOI · Paper page
- Lin, 2011, Hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum, J. Hepatol., 54, 666, 10.1016/j.jhep.2010.07.031 · DOI · Paper page
- Gao, 2012, Definitive diagnosis of hepatic sinusoidal obstruction syndrome induced by pyrrolizidine alkaloids, J. Dig. Dis., 13, 33, 10.1111/j.1751-2980.2011.00552.x · DOI · Paper page
- Lai, 2012, Clinical and pathological features in 138 cases of drug-induced liver injury, Zhonghua Gan Zang Bing Za ZhiZhonghua Ganzangbing Zazhi Chin. J. Hepatol., 20, 185
- Dong, 2014, Eighteen cases of liver injury following ingestion of Polygonum multiflorum, Complement. Med., 22, 70, 10.1016/j.ctim.2013.12.008 · DOI · Paper page
- Gao, 2015, Blood pyrrole-protein adducts as diagnostic and prognostic index in pyrrolizidine alkaloid-hepatic sinusoidal obstruction syndrome, Drug Des. Dev., 9, 4861
- Wang, 2015, Evidence chain-based causality identification in herb-induced liver injury: Exemplification of a well-known liver-restorative herb Polygonum multiflorum, Front. Med., 9, 457, 10.1007/s11684-015-0417-8 · DOI · Paper page
- Zhu, 2015, Clinical analysis of drug-induced liver injury caused by Polygonum multiflorum and its preparations, Zhongguo Zhong Xi Yi Jie He Za Zhi, 35, 1442
- Zhang, P., Ye, Y., Yang, X., and Jiao, Y. (2016). Systematic review on Chinese herbal medicine induced liver injury. Evid.-Based Complement. Altern. Med. · DOI · Paper page
- Li, 2017, Idiosyncratic drug-induced liver injury linked to Polygonum multiflorum: A case study by pharmacognosy, Chin. Integr. Med., 23, 625, 10.1007/s11655-017-2543-9 · DOI · Paper page
- Chow, 2019, Medicine herbs-induced liver injury from an oncological perspective with RUCAM, Integr. Cancer, 18, 1
- Jing, 2019, Association between the concurrence of pre-existing chronic liver disease and worse prognosis in patients with an herb-Polygonum multiflorum thunbinduced liver injury: A case-control study from a specialised liver disease center in China, BMJ Open, 9, e023567, 10.1136/bmjopen-2018-023567 · DOI · Paper page
- Li, A., Gao, M., Zhao, N., Li, P., Zhu, J., and Li, W. (2019). Acute liver failure associated with Fructus Psoraleae: A case report and literature review. BMC Complement. Altern. Med., 19. · DOI · Paper page
- Ni, 2019, Polygonum multiflorum-induced liver injury: Clinical characteristics, risk factors, material basis, action mechanism and current challenges, Front. Pharmacol., 10, 1467, 10.3389/fphar.2019.01467 · DOI · Paper page
- Tan, 2019, RUCAM-based assessment of liver injury by xian-tian-guo (Swietenia macrophylla) seeds, a plant used for treatment of hypertension and diabetes, Ann. Hepatol., 18, 403, 10.1016/j.aohep.2019.01.003 · DOI · Paper page
- Zhu, 2019, Predictors of poor outcomes in 488 patients with herb-induced liver injury, Turk. J. Gastroenterol., 30, 47
- Gao, Y., Wang, Z., Tang, J., Liu, X., Shi, W., Qin, N., Wang, X., Pang, Y., Li, R., and Zhang, Y. (2020). New incompatible pair of TCM: Epimedii Folium combined with Psoraleae Fructus induces idiosyncratic hepatotoxicity under immunological stress conditions. Front. Med., 28. · DOI
- Xia, 2020, Causality assessment of skyfruit-induced liver injury using the updated RUCAM: A case report and review of the literature, J. Int. Med. Res., 48, 300060520917569, 10.1177/0300060520917569 · DOI
- Restrepo, 2006, Acute hepatitis due to shen-min: A herbal product derived from Polygonum multiflorum, J. Clin. Gastroenterol., 40, 629, 10.1097/00004836-200608000-00014 · DOI
- Parlati, 2017, Aloe vera-induced acute liver injury: A case report and literature review, Clin. Res. Hepatol. Gastroenterol., 41, e39, 10.1016/j.clinre.2016.10.002 · DOI
- Teschke, 2009, Severe hepatotoxicity by Indian Ayurvedic herbal products: A structured causality assessment, Ann. Hepatol., 8, 258, 10.1016/S1665-2681(19)31777-6 · DOI · Paper page
- Teschke, 2011, Herbal hepatotoxicity by Greater Celandine (Chelidonium majus): Causality assessment of 22 spontaneous reports, Regul. Toxicol. Pharm., 61, 282, 10.1016/j.yrtph.2011.08.008 · DOI
- Teschke, 2012, Suspected Greater Celandine hepatotoxicity: Liver specific causality evaluation of published case reports from Europe, Eur. J. Gastroenterol. Hepatol., 24, 270, 10.1097/MEG.0b013e32834f993f · DOI
- Douros, A., Bronder, E., Andersohn, F., Klimpel, A., Kreutz, R., Garbe, E., and Bolbrinker, J. (2016). Herb-induced liver injury in the Berlin Case-Control Surveillance Study. Int. J. Mol. Sci., 17. · DOI
- Teschke, 2015, Traditional Chinese Medicine and herbal hepatotoxicity: A tabular compilation of reported cases, Ann. Hepatol., 14, 7, 10.1016/S1665-2681(19)30796-3 · DOI · Paper page
200 of 242 shown
Cited by
AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury
Fontana, R. J., Liou, I., Reuben, A., Suzuki, A., Fiel, M. I., Lee, W., & Navarro, V. (2023) · Hepatology · doi:10.1002/hep.32689 · Cited by 340
“Furthermore, consideration of other causes of liver injury may have been overlooked or unappreciated when the tools were first developed.[75,118] For example, there is no requirement for testing for acute HCV or HEV infection, and there are few good data to justify inclusion of risk factors as listed in the RUCAM.”
BackgroundDrug induced liver injury – a 2023 update
Allison, R., Guraka, A., Shawa, I. T., Tripathi, G., Moritz, W., & Kermanizadeh, A. (2023) · Journal of Toxicology and Environmental Health, Part B · doi:10.1080/10937404.2023.2261848 · Cited by 167
“Recently, Teschke and Danan (2020) found that the RUCAM model was used to assess possible cases of idiosyncratic DILI in 81,856 published reports listed on PubMed since 1993.”
MethodSwanson, L. A., Kassab, I., Tsung, I., Schneider, B. J., & Fontana, R. J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.984940 · Cited by 23
Huang, Y.-S., Chang, T.-T., Peng, C.-Y., Lo, G.-H., Hsu, C.-W., Hu, C.-T., & Huang, Y.-H. (2021) · Hepatology International · doi:10.1007/s12072-021-10241-3 · Cited by 17
Jędrejko, K., Lazarev, A., Jędrejko, M., & Muszyńska, B. (2024) · Food Reviews International · doi:10.1080/87559129.2023.2238055 · Cited by 4
Metadata
- Authors
- Teschke, R., & Danan, G.
- Affiliations
- Department of Internal Medicine II, Division of Gastroenterology and Hepatology, Klinikum Hanau, D-63450 Hanau, Teaching Hospital of the Medical Faculty of the Goethe University, D-60590 Frankfurt/Main, Germany
- Pharmacovigilance Consultancy, F-75020 Paris, France
- Venue
- Medicines
- Publisher
- MDPI AG
- Published
- 2020-09-29
- Volume
- 7
- Issue
- 10
- Pages
- 62
- ISSN
- 2305-6320
- Cited by
- 77
- References
- 13
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Worldwide Use of RUCAM for Causality Assessment in 81,856 Idiosyncratic DILI and 14,029 HILI Cases Published 1993–Mid 2020: A Comprehensive Analysis. https://app.cochat.ai/papers/10.3390/medicines7100062
- The paper
- Teschke, R., & Danan, G. (2020). Worldwide Use of RUCAM for Causality Assessment in 81,856 Idiosyncratic DILI and 14,029 HILI Cases Published 1993–Mid 2020: A Comprehensive Analysis. Medicines. https://doi.org/10.3390/medicines7100062
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.